A phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumours.

S.C. Pacey, Richard Wilson, M. Walton, Martin Eatock, A. Hardcastle, H. Zetterlund, H- Arkenau, R. Beecham, W. Aherne, J.S. De Bono, F. Raynaud, P. Workman, I. Judson

Research output: Contribution to journalArticlepeer-review

169 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumours.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science